Overview
BBIO market data
Price History
BBIO price chart
Valuation & Profitability
No Valuation Data Yet
Alpha Vantage and Twelve Data both returned no valuation metrics for BBIO. Check back after the next daily valuation refresh — this symbol may be new, delisted, or temporarily unavailable from both providers.
Company news
8-K filing — BridgeBio Pharma, Inc. (BBIO)SEC EDGAR · Jul 22, 2026, 8:34 PM
BridgeBio Pharma Announces FDA Accepts For Filing Its New Drug Application For Encaleret To Treat Autosomal Dominant Hypocalcemia Type 1Benzinga · Jul 22, 2026, 11:31 AM
Citigroup Maintains Neutral on BridgeBio Pharma, Raises Price Target to $93Benzinga · Jul 16, 2026, 8:20 PM
Keysight To Rally Over 24%? Here Are 10 Top Analyst Forecasts For MondayBenzinga · Jul 13, 2026, 12:11 PM
HC Wainwright & Co. Maintains Buy on BridgeBio Pharma, Raises Price Target to $120Benzinga · Jul 13, 2026, 10:24 AM
Ionis, AstraZeneca Stumble in ATTR-CM Trial as Rivals Stand to GainBenzinga · Jul 10, 2026, 3:35 PM
Aehr Test Systems, Lam Research, Applied Materials And Other Big Stocks Moving Higher On ThursdayBenzinga · Jul 9, 2026, 2:05 PM
Transthyretin Amyloidosis Treatment Market Size to Reach USD 35.10 Billion by 2035, Growing at a 14.64% CAGR | SNS InsiderGlobenewswire Inc · Jul 7, 2026, 11:15 AM
BridgeBio Announces Publication Of New Analyses In Circulation: Heart Failure, Examining Kidney Function In Individuals With Transthyretin Amyloid Cardiomyopathy Treated With AcoramidisBenzinga · Jul 2, 2026, 11:40 AM
Wall Street Thinks This Biotech Stock Can Soar 45%. Here's Why Analysts Are Right.The Motley Fool · Jul 2, 2026, 11:15 AM